Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Sqz Biotechnologies Co.
Headquarters: Watertown, MA, United States of America
Website: N/A
Year Founded: 2013
Status: Out of Business
BioCentury | Jan 7, 2023
Management Tracks
Schulman named chair of Alnylam, Bertozzi joins board
Plus: Estigarribia becomes InterVenn CEO and updates from Lyndra, Catalio, Pneumagen and more
BioCentury | Jan 6, 2023
Management Tracks
Singhal to lead development at Biogen as company splits R&D
Plus: Baumal named CMO at Apellis, and updates from Pheast, Sofinnova Partners, GE, Lexeo and more
BioCentury | Dec 2, 2022
Regulation
Dec. 1 Quick Takes: FDA approves Rigel, Forma therapy for AML
Plus: Pfizer, Roivant form new unit around ulcerative colitis target, China’s Trinomab raises over $100M and updates from Nordic-APIM, Nectin, NIST and more
BioCentury | Jun 2, 2022
Management Tracks
Anderson to lead Pfizer’s vaccine R&D
Plus CFO Luca Scavo resigns from Evelo, Passage Bio’s CEO steps down, and updates from MindMaze, Black Diamond and more
BioCentury | Apr 9, 2022
Discovery & Translation
SomaLogic’s cardiovascular risk surrogate; plus SQZ, Alpine and more
BioCentury’s roundup of translational news
BioCentury | Nov 17, 2021
Management Tracks
Rhee steps down as CEO of Korea’s SCM
Recludix, Ankyra unveil venture rounds and new execs; plus ImmunoGen, Talis, Kira, Sonoma, Spruce, Ankyra and more
BioCentury | Sep 20, 2021
Finance
Eyeing bigger deals, Illumina Ventures closes $325M second fund
Genomics-focused firm’s latest vehicle will span therapeutics, tools, diagnostics and digital health
BioCentury | Nov 3, 2020
Management Tracks
Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more
Gene therapy developer Freeline Therapeutics Holdings plc (NASDAQ:FRLN) hired Mark Baldry as chief commercial officer. He previously held the same role at Wave Life Sciences Ltd. (NASDAQ:WVE).
BioCentury | Oct 31, 2020
Finance
Data Byte: at $1.9B valuation, Atea leads this week’s IPOs
Atea led the pack of IPOs priced in the final week before the U.S. election, trading up 26% to $30.34 on its first day of trading Friday after raising $300 million. The upsized offering valued
BioCentury | Oct 27, 2020
Finance
With $1.8B valuation within reach, Sommadossi’s Atea readies ‘mega-IPO’
Cell therapy play SQZ also sets terms for NASDAQ IPO
Items per page:
1 - 10 of 33